Reviewed listing: NASDAQ:ANAB · Analysis dated Oct 21, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Anaptys receives contractual shares of drug revenue. Its own research was spun out into First Tracks in April.
What supports the business?
Jemperli is already being sold. Rising sales could later generate significantly higher revenue for Anaptys.
What could improve?
Further approved uses and the end of the revenue assignment to Sagard could make more cash available to shareholders. The timing of both is uncertain.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At present, 45.43 USD is not a sufficiently substantiated attractive entry point. Most of the reported high profit is not recurring cash flow.
What is the main risk?
The stock depends heavily on Jemperli, agreements with GSK, and an unresolved legal dispute. For now, the assigned revenues flow first to a financing partner.
What is the overall assessment?
After spinning off its research, Anaptys primarily manages interests in drug revenue. Jemperli is growing, but a financial partner initially receives the related revenue. At 45.43 USD, a favorable share price is not sufficiently supported given unresolved legal and payment developments. Watch.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in